Bristol Myers Squibb (NYSE:BMY) Issues FY 2026 Earnings Guidance

Bristol Myers Squibb (NYSE:BMY) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 6.050-6.350 for the period, compared to the consensus estimate of 6.040. The company issued revenue guidance of $46.0 billion-$47.5 billion, compared to the consensus revenue estimate of $44.2 billion.

Bristol Myers Squibb Trading Up 4.9%

BMY stock opened at $58.76 on Thursday. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $63.33. The company has a market cap of $119.62 billion, a P/E ratio of 19.85, a PEG ratio of 0.17 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. The business has a fifty day moving average of $53.88 and a 200-day moving average of $48.85.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.During the same period last year, the firm posted $1.67 earnings per share. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts expect that Bristol Myers Squibb will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is 85.14%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Leerink Partners increased their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Morgan Stanley reiterated an “underweight” rating and set a $37.00 target price (up previously from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Seven research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and an average target price of $57.43.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMS issued an upbeat 2026 forecast and told investors it expects price cuts for Eliquis to boost revenue next year — management says 2026 guidance is above Street estimates, which is driving optimism. Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off
• Positive Sentiment: Company reported revenue of about $12.5B (a beat) and cited immuno‑oncology sales growth that helped offset declines in older drugs — evidence of durable growth drivers. Bristol Myers Squibb Revenue Ticks Up on Immuno‑Oncology Growth
• Positive Sentiment: Company press release and slide deck outline the results and the strategic priorities underpinning the outlook (revenue beat, pipeline and cost actions). Bristol Myers Squibb Reports Fourth Quarter and Full‑Year Financial Results for 2025
• Positive Sentiment: BMS expanded a multi‑year manufacturing (lentiviral vector) supply agreement with OXB to support CAR‑T programs — strengthens CDMO capacity for cell & gene programs and de‑risk supply for growth assets. OXB Signs New Multi‑Year Commercial Supply Agreement with Bristol Myers Squibb
• Neutral Sentiment: Analysts and media are parsing the quarter and guidance; commentary has increased volatility as investors weigh the guidance, manufacturing deal and pipeline cadence. What’s Going On With Bristol‑Myers Squibb Stock Today?
• Negative Sentiment: Reported EPS of $1.26 (GAAP) missed consensus by roughly $0.39 on the cited figures — that headline miss can weigh on near‑term sentiment despite non‑GAAP beats. Bristol Myers Squibb Q4 Results (Press Release/Deck)
• Negative Sentiment: Legacy franchises remain under pressure from generics and pricing dynamics; the company is depending on newer drugs (e.g., Reblozyl and immuno‑oncology) to offset declines — a structural headwind to watch. Will Reblozyl Shine in Bristol Myers’ Fourth‑Quarter Results?

Institutional Trading of Bristol Myers Squibb

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Binnacle Investments Inc boosted its position in Bristol Myers Squibb by 17.0% during the 2nd quarter. Binnacle Investments Inc now owns 1,801 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 262 shares during the period. E Fund Management Co. Ltd. boosted its holdings in Bristol Myers Squibb by 2.6% in the second quarter. E Fund Management Co. Ltd. now owns 10,409 shares of the biopharmaceutical company’s stock valued at $482,000 after acquiring an additional 267 shares in the last quarter. New England Asset Management Inc. increased its position in Bristol Myers Squibb by 0.8% during the 3rd quarter. New England Asset Management Inc. now owns 40,036 shares of the biopharmaceutical company’s stock valued at $1,806,000 after purchasing an additional 315 shares during the period. Keystone Financial Group boosted its stake in shares of Bristol Myers Squibb by 4.9% during the 3rd quarter. Keystone Financial Group now owns 7,136 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 332 shares in the last quarter. Finally, Financial Advisors Network Inc. increased its position in shares of Bristol Myers Squibb by 7.7% during the second quarter. Financial Advisors Network Inc. now owns 5,041 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 359 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.